Cytokinetics to present at 2026 RBC Healthcare Conference, advancing cardiac drug pipeline.

Cytokinetics announced its management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 19, 2026. The company, specializing in cardiovascular biopharmaceuticals, is advancing several cardiac drugs including MYQORZO® (aficamten), approved for obstructive hypertrophic cardiomyopathy, and investigational drugs omecamtiv mecarbil and ulacamten for heart failure. Positive Phase 3 trial results for aficamten in non-obstructive hypertrophic cardiomyopathy are set to be presented soon, with ongoing discussions planned with regulatory authorities. The webcast of the event will be available on Cytokinetics' website for 90 days.